Shares of Invitae Corp (NYSE: NVTA) came under pressure on Monday, after gaining more than 24% in January.
Despite having a restricting plan in place, the biotech company has a “long path to profitability,” according to Goldman Sachs.
On CNBC’s "Halftime Report Final Trades," Liz Young of BNY Mellon Investment Management named the SPDR S&P Biotech ETF (NYSE: XBI), saying if you "want growth,
On CNBC’s "Halftime Report Final Trades," Bryn Talkington of Requisite Capital Management named Viper Energy Partners LP (NASDAQ: VNOM), which is a subsid